Vanta Bioscience

Vanta Bioscience Gross Margin

The Gross Margin of Vanta Bioscience (540729.BO) as of Nov 18, 2026 is 32.01 %. In the previous year, Gross Margin was 92.59 % — a change of -65.43% (lower).

Gross Margin

32.01 %

YoY

-65.43%

Last updated:

Gross Margin of Vanta Bioscience is 2025 32.01 % . Gross Margin of Vanta Bioscience was 2024 92.59 % . It decreases by -65.43% lower compared to the previous year.

For Vanta Bioscience, the gross margin of 32.0% is down versus 91.8% a few years ago.

The Vanta Bioscience Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
91.91 INR
Jan 1, 2019
89.39 INR
Jan 1, 2020
91.66 INR
Jan 1, 2021
91.84 INR
Jan 1, 2022
92.75 INR
Jan 1, 2023
84.90 INR
Jan 1, 2024
92.59 INR
Jan 1, 2025
32.01 INR
The Vanta Bioscience Gross Margin history
YEARGross MarginYoY
32.01 %-65.43%
92.59 %+9.06%
84.90 %-8.47%
92.75 %+0.99%
91.84 %+0.20%
91.66 %+2.54%
89.39 %-2.74%
91.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vanta Bioscience Stock analysis

What does Vanta Bioscience do? Vanta Bioscience Ltd. generates revenue by offering comprehensive preclinical contract research services to pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. The company provides preclinical safety assessment services, risk assessment for active pharmaceutical ingredients (API), excipients, extractable and leachable substances, and pharmaceutical impurities. It also delivers health-based exposure limit determinations including permitted daily exposure (PDE), allowable daily exposure (ADE), and occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's clients across diverse sectors rely on its analytical testing, environmental studies, and research services for regulatory compliance and product safety validation. Vanta Bioscience Ltd. operates as a full-service preclinical contract research organization with a focus on delivering specialized safety assessments and exposure limit evaluations to support client product development and market entry. Its service portfolio includes clinical research, pre-clinical research, biopharma services, analytical testing, and environmental studies, catering to industries requiring rigorous safety evaluations before product launch. The company's expertise in risk assessment for pharmaceutical ingredients and related substances enables it to serve a broad range of clients in the biopharma and chemical sectors. Vanta Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vanta Bioscience stock

Gross Margin of Vanta Bioscience is 32.01 % in 2025.

Gross Margin of Vanta Bioscience changed from 92.59 % to 32.01 %, representing a -65.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Vanta Bioscience since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Vanta Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Vanta Bioscience

All Key Metrics — Vanta Bioscience